This is a routine governance filing with no immediate trading catalyst. Monitor for upcoming clinical data readouts on ADC pipeline (HWK-007, HWK-016, HWK-206) and any future capital raises, as the company remains a clinical-stage biotech with ongoing financing needs.
Price Chart
Executive Summary
Whitehawk Therapeutics appointed Vijay Iyengar, M.D., a former Incyte executive, to its board of directors, filling a newly created seat. This is a routine board expansion with no material financial impact, and the appointment of an experienced oncology executive is a modest positive for governance credibility at a clinical-stage biotech. No financial data, guidance changes, or operational updates were included in the filing.
Key Facts
- Board expanded from 9 to 10 directors with the appointment of Vijay Iyengar, M.D., effective September 9, 2026.
- Dr. Iyengar served as EVP at Incyte Corporation (Nasdaq: INCY) from May 2022 to November 2025 and held prior senior roles at Novartis and McKinsey.
- Dr. Iyengar received an initial stock option grant for 76,080 shares, vesting monthly over three years, plus a $40,000 annual cash retainer.
- No family relationships, arrangements, or related-party transactions were disclosed in connection with the appointment.
Financial Impact
Routine director appointment with standard equity compensation — no material financial impact.
Risk Factors
- Clinical-stage biotech with no approved products — pipeline execution risk remains the primary driver.
- No financial data or guidance provided in this filing — limited actionable information for traders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-388010 |
| Document: d160342dex991.htm | 0001193125-26-388010 |
| Document: 0001193125-26-388010-index-headers.html | 0001193125-26-388010 |
| Document: 0001193125-26-388010-index.html | 0001193125-26-388010 |
| Document: 0001193125-26-388010.txt | 0001193125-26-388010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | 8-K | $4.11 $4.07 | ▼ −0.97% | ▼ −0.53% | $3.14 (−23.60%) |
Aug 6, 2026 11w ago | 8-K | $4.70 $4.76 | ▲ +1.28% | ▲ +0.67% | $3.14 (−33.19%) |
Jun 10, 2026 19w ago | EFFECT | $4.02 $4.06 | ▼ −0.99% | ▲ +0.70% | $3.14 (+21.89%) |
May 29, 2026 21w ago | S-3 | $4.49 $4.18 | ▲ +6.90% | ▲ +7.06% | $3.14 (+30.07%) |
May 13, 2026 23w ago | 8-K | $4.93 $5.10 | ▼ −3.45% | ▼ −2.67% | $3.14 (+36.31%) |
May 7, 2026 24w ago | 8-K | $3.94 $3.97 | ▲ +0.76% | ▼ −0.07% | $3.14 (−20.30%) |
Apr 8, 2026 28w ago | Insider Cluster | $3.55 $3.39 | ▲ +4.51% | ▲ +4.45% | $3.14 (+11.55%) |
Apr 8, 2026 28w ago | Insider Cluster | $3.55 $3.39 | ▲ +4.51% | ▲ +4.45% | $3.14 (+11.55%) |
Apr 8, 2026 28w ago | Insider Cluster | $3.55 $3.39 | ▲ +4.51% | ▲ +4.45% | $3.14 (+11.55%) |
Mar 12, 2026 32w ago | 8-K | $3.90 $3.91 | ▲ +0.26% | ▲ +0.85% | $3.14 (−19.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers